Axsome Therapeutics, Inc. | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Company Directory for Axsome Therapeutics, Inc.

Team Bitscale

13 Feb 2026 — 1 min read

Axsome Therapeutics, Inc.

Overview

Axsome Therapeutics, Inc. is a biopharmaceutical company based in New York, founded in January 2012 by Dr. Herriot Tabuteau, Chairman and CEO. The organization specializes in developing and commercializing innovative therapies for central nervous system (CNS) disorders with limited treatment options. Axsome advances drug candidates through clinical trials and regulatory approvals to address unmet needs in the CNS landscape.

The company has reached significant milestones, including its initial public offering in 2015, positive Phase 3 results for AXS-05 in 2019, and the FDA approval of Auvelity™ in 2022 for major depressive disorder. In 2023, Axsome launched Auvelity™, generating $130.1 million in net product revenue, along with $65.7 million from its Sunosi product. Ongoing development efforts target a wide range of CNS conditions.

Basic Information

Industry	research
Founded	2012
Revenue	$385.7M
Headquarters	One World Trade Center, New York, NY 10007, United States
Languages	English

Contact Details

Key Focus Areas & Initiatives

Biopharmaceuticals for CNS disorders
Major depressive disorder treatments
Drug repurposing and therapeutic innovation
Market access strategy and commercialization
Regulatory expertise and pipeline development
Clinical trial expertise
FDA approvals and orphan drug designation
Product Sunosi and Auvelity™ launch
Migraine, narcolepsy, and sleep disorder therapies
Patent portfolio protection
Mental health and neurological condition research
Patient-focused solutions
Drug formulation and intellectual property
Strategic acquisitions and asset integration
Internal R&D and biotech innovation
Market growth and expansion
Therapeutics for high unmet medical need
Oral antidepressant development
Clinical-stage to commercial strategy
Healthcare and life sciences advancements

Technologies Used

ASP.NET
CloudFlare Hosting
Cloudflare DNS
Google Tag Manager
Microsoft Office 365
Microsoft-IIS
Mobile Friendly
Outlook
Remote
Salesforce
Slack
SparkPost
WordPress.org
reCAPTCHA

Affiliated Organizations & Regional Branches

SUNOSI

GTM Strategy: The Complete Guide (Framework, Examples & B2B Playbook)

Most things labeled a “GTM strategy” are really a channel checklist wearing a nice slide template. They are activity plans, not a coherent answer to how the business will create, capture, and deliver value for a specific buyer in a specific market. This is written for B2B founders, product marketers,

How Scrut.io Built a Compliance-Signal GTM Machine with Bitscale

Scrut Automation simplifies continuous compliance for cloud-native companies, helping them achieve ISO 27001, SOC 2, PCI DSS, and GDPR compliance 5x faster — with real-time risk monitoring and automated evidence collection.

Clay API Limits, Authentication & Rate Limits Explained

Your enrichment workflow ran perfectly on 50 test records. Then you pointed it at 10,000 contacts and everything collapsed: 429 errors, duplicate CRM writes, and a credit balance that evaporated overnight. The Clay API usually is not the root cause. The root cause is treating authentication, rate limits, and

GTM Data Stack for US Outbound Teams

Outbound has changed. Spray-and-pray cadences that worked five years ago now burn through contact lists, damage sender reputation, and leave revenue teams short on pipeline. What separates high-performing US outbound teams in 2026 is not effort or headcount. It is the quality, governance, and architecture of the GTM Data Stack.